Barclays
IPSC icon

Barclays’s Century Therapeutics IPSC Stock Holding History

Barclays’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.5K Sell
24,700
-95,532
-79% -$218K ﹤0.01% 4252
2026
Q1 		$272K Buy
120,232
+120,231
+12,023,100% +$253K ﹤0.01% 3521
2025
Q4 		$1 Hold
1
– – ﹤0.01% 5191
2025
Q3 		$0 Sell
1
-12,196
-100% -$6.58K ﹤0.01% 5605
2025
Q2 		$6.82K Sell
12,197
-35,012
-74% -$18.8K ﹤0.01% 4946
2025
Q1 		$22.5K Sell
47,209
-23,266
-33% -$17.5K ﹤0.01% 4775
2024
Q4 		$71.2K Buy
70,475
+8,530
+14% +$11.6K ﹤0.01% 4667
2024
Q3 		$106K Buy
61,945
+45,797
+284% +$89.7K ﹤0.01% 4558
2024
Q2 		$41.2K Sell
16,148
-315
-2% -$996 ﹤0.01% 4283
2024
Q1 		$68.8K Sell
16,463
-15,721
-49% -$66.5K ﹤0.01% 4543
2023
Q4 		$107K Buy
32,184
+28,035
+676% +$51.1K ﹤0.01% 4624
2023
Q3 		$8.3K Sell
4,149
-520
-11% -$1.38K ﹤0.01% 4329
2023
Q2 		$14.8K Sell
4,669
-5,616
-55% -$18.1K ﹤0.01% 4177
2023
Q1 		$35.7K Buy
10,285
+4,877
+90% +$21.4K ﹤0.01% 4523
2022
Q4 		$27.7K Buy
5,408
+4,554
+533% +$43K ﹤0.01% 4745
2022
Q3 		$8K Sell
854
-156
-15% -$1.64K ﹤0.01% 4390
2022
Q2 		$8K Sell
1,010
-1,805
-64% -$17.7K ﹤0.01% 4693
2022
Q1 		$36K Buy
+2,815
New +$37.3K ﹤0.01% 4241

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Barclays's IPSC Position: Q2 2026 in Review

Barclays reduced its Century Therapeutics (IPSC) stake by 79% in Q2 2026, selling an estimated $218K and leaving 24,700 shares worth $60.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4252.

Barclays first reported a position in IPSC in Q1 2022 and has held it in 18 quarters since. The position peaked at $272K in Q1 2026. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • Barclays held 24,700 shares of Century Therapeutics worth $60.5K as of Q2 2026.
  • Barclays sold 95,532 Century Therapeutics shares in Q2 2026, an estimated $218K.
  • Century Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4252 holding.
  • Barclays first reported a position in Century Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Century Therapeutics position peaked at $272K in Q1 2026.
  • 99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.